Abstract
| Original language | English |
|---|---|
| Article number | 5694 |
| Pages (from-to) | 5694 |
| Number of pages | 1 |
| Journal | International Journal of Molecular Sciences |
| Volume | 23 |
| Issue number | 10 |
| Early online date | 19 May 2022 |
| DOIs | |
| Publication status | Published (in print/issue) - 19 May 2022 |
Bibliographical note
Funding Information:This research was funded by the Association pour la Recherche sur la Sclérose latérale amyotrophique et autres maladies du motoneurone (ARSla, France, contract R11010DD, to PFP, contracts R17050DD, S.3200.ARSLA.1, to SM), the Association Française contre les Myopathies (AFM, France, #19466, to SM), the Aide à la Recherche des Maladies du Cerveau association (ARMC, France, contract R16009DD, to SM) and the Fédération pour la Recherche sur le Cerveau (FRC, France, contract AO‐FRC 2009 #33536, to SM). Lentiviral transgenesis technology was funded by GlaxoSmithKline research support (contract CT110725). A Stafford Fox Medical Research Foundation Grant supported BJT. The Florey Institute of Neuroscience and Mental Health acknowledges the strong support from the Victorian Government and in particular the funding from the Operational Infrastructure Support Grant. ET was supported by a PhD Fellowship from AFM (#18145) and benefited from a student exchange program between ICM (France) and the Florey Institute of Neuroscience and Mental Health (Australia).We acknowledge the patients and their family. We thank the Généthon cell and DNA bank (Evry, France) and the ICM DNA and cell bank (Paris, France) for patient DNA and lymphoblasts. We thank the UMS 28 (for lentiviral transgenesis) and the following ICM core facilities (Paris, France) for equipment access: CELIS (cell culture), iVector (lentiviral production), PHENO‐ICMice (mouse phenotyping) and HISTOMICS (tissue slides) which received funding from the program “Investissements d’avenir” ANR‐10‐IAIHU‐06.
Funding Information:
Acknowledgments: We acknowledge the patients and their family. We thank the Généthon cell and DNA bank (Evry, France) and the ICM DNA and cell bank (Paris, France) for patient DNA and lymphoblasts. We thank the UMS 28 (for lentiviral transgenesis) and the following ICM core facili‐ ties (Paris, France) for equipment access: CELIS (cell culture), iVector (lentiviral production), PHENO‐ICMice (mouse phenotyping) and HISTOMICS (tissue slides) which received funding from the program “Investissements d’avenir” ANR‐10‐IAIHU‐06.
Funding Information:
Funding: This research was funded by the Association pour la Recherche sur la Sclérose latérale amyotrophique et autres maladies du motoneurone (ARSla, France, contract R11010DD, to PFP, contracts R17050DD, S.3200.ARSLA.1, to SM), the Association Française contre les Myopathies (AFM, France, #19466, to SM), the Aide à la Recherche des Maladies du Cerveau association (ARMC, France, contract R16009DD, to SM) and the Fédération pour la Recherche sur le Cerveau (FRC, France, contract AO‐FRC 2009 #33536, to SM). Lentiviral transgenesis technology was funded by GlaxoSmithKline research support (contract CT110725). A Stafford Fox Medical Research Founda‐ tion Grant supported BJT. The Florey Institute of Neuroscience and Mental Health acknowledges the strong support from the Victorian Government and in particular the funding from the Opera‐ tional Infrastructure Support Grant. ET was supported by a PhD Fellowship from AFM (#18145) and benefited from a student exchange program between ICM (France) and the Florey Institute of Neuroscience and Mental Health (Australia).
Publisher Copyright:
© 2022 by the authors. Licensee MDPI, Basel, Switzerland.
Funding
Funding Information: This research was funded by the Association pour la Recherche sur la Sclérose latérale amyotrophique et autres maladies du motoneurone (ARSla, France, contract R11010DD, to PFP, contracts R17050DD, S.3200.ARSLA.1, to SM), the Association Française contre les Myopathies (AFM, France, #19466, to SM), the Aide à la Recherche des Maladies du Cerveau association (ARMC, France, contract R16009DD, to SM) and the Fédération pour la Recherche sur le Cerveau (FRC, France, contract AO‐FRC 2009 #33536, to SM). Lentiviral transgenesis technology was funded by GlaxoSmithKline research support (contract CT110725). A Stafford Fox Medical Research Foundation Grant supported BJT. The Florey Institute of Neuroscience and Mental Health acknowledges the strong support from the Victorian Government and in particular the funding from the Operational Infrastructure Support Grant. ET was supported by a PhD Fellowship from AFM (#18145) and benefited from a student exchange program between ICM (France) and the Florey Institute of Neuroscience and Mental Health (Australia).We acknowledge the patients and their family. We thank the Généthon cell and DNA bank (Evry, France) and the ICM DNA and cell bank (Paris, France) for patient DNA and lymphoblasts. We thank the UMS 28 (for lentiviral transgenesis) and the following ICM core facilities (Paris, France) for equipment access: CELIS (cell culture), iVector (lentiviral production), PHENO‐ICMice (mouse phenotyping) and HISTOMICS (tissue slides) which received funding from the program “Investissements d’avenir” ANR‐10‐IAIHU‐06. Funding Information: Acknowledgments: We acknowledge the patients and their family. We thank the Généthon cell and DNA bank (Evry, France) and the ICM DNA and cell bank (Paris, France) for patient DNA and lymphoblasts. We thank the UMS 28 (for lentiviral transgenesis) and the following ICM core facili‐ ties (Paris, France) for equipment access: CELIS (cell culture), iVector (lentiviral production), PHENO‐ICMice (mouse phenotyping) and HISTOMICS (tissue slides) which received funding from the program “Investissements d’avenir” ANR‐10‐IAIHU‐06. Funding Information: Funding: This research was funded by the Association pour la Recherche sur la Sclérose latérale amyotrophique et autres maladies du motoneurone (ARSla, France, contract R11010DD, to PFP, contracts R17050DD, S.3200.ARSLA.1, to SM), the Association Française contre les Myopathies (AFM, France, #19466, to SM), the Aide à la Recherche des Maladies du Cerveau association (ARMC, France, contract R16009DD, to SM) and the Fédération pour la Recherche sur le Cerveau (FRC, France, contract AO‐FRC 2009 #33536, to SM). Lentiviral transgenesis technology was funded by GlaxoSmithKline research support (contract CT110725). A Stafford Fox Medical Research Founda‐ tion Grant supported BJT. The Florey Institute of Neuroscience and Mental Health acknowledges the strong support from the Victorian Government and in particular the funding from the Opera‐ tional Infrastructure Support Grant. ET was supported by a PhD Fellowship from AFM (#18145) and benefited from a student exchange program between ICM (France) and the Florey Institute of Neuroscience and Mental Health (Australia). Publisher Copyright: © 2022 by the authors. Licensee MDPI, Basel, Switzerland.
UN SDGs
This output contributes to the following UN Sustainable Development Goals (SDGs)
-
SDG 3 Good Health and Well-being
Keywords
- ALS
- genetics
- mutations
- alternative autophagy
- RAB9
- mitochondrial homeostasis
- post-mortem spinal cord
- lymphoblasts
- transgenic mice
- NSC-34 cell line
- Profilins - genetics - metabolism
- rab GTP-Binding Proteins - metabolism
- Humans
- Homeostasis
- Mitochondria - metabolism
- Animals
- Amyotrophic Lateral Sclerosis - metabolism
- Mice
- Autophagy - genetics
- Mutation
Fingerprint
Dive into the research topics of 'The Amyotrophic Lateral Sclerosis M114T PFN1 Mutation Deregulates Alternative Autophagy Pathways and Mitochondrial Homeostasis'. Together they form a unique fingerprint.Cite this
- APA
- Author
- BIBTEX
- Harvard
- Standard
- RIS
- Vancouver